Abstract 84P
Background
Tumor-specific neoantigens arising from non-synonymous mutations have become increasingly attractive targets for immunotherapies. The accurate identification and prioritization of neoantigens is crucial to design personalized therapies for each cancer patient. Putative immunogenic neoantigens are currently selected by using several peptide-HLA-I binding predictors. While HLA-I binding affinity is essential to tumor cell presentation of neoantigens, it is insufficient to determine neoantigen immunogenicity. As such, the vast majority of predicted tumor neoantigens (98%) are not immunogenic and ineffective in activating antitumor responses. To address this challenge, we propose integrating T-cell receptor (TCR) repertoire profiles of tumor infiltrating lymphocytes (TILs), a key determinant of immunogenicity, in the current neoantigen prediction workflow.
Methods
We sequenced the CDR3 regions of TCR beta chain (TCRB) repertoire in 27 colorectal cancer (CRC) patients and predicted neopeptide-TCR binding by using our previously published predictor, epiTCR and another existing tool pMTNet. We constructed a machine learning model which considers both peptide-HLA-I and peptide-TCR binding features to prioritize high quality immunogenic neoantigen candidates. We further performed ELISpot assay on autologous PBMCs from four CRC patients to experimentally validate the effectiveness of our model. Finally, we selected the highest immunogenic candidate to perform 10X single-cell sequencing to identify the potential neoantigen-specific TCRs for cell-based vaccine development.
Results
We showed that 5.5% of neopeptide candidates despite having weak HLA-I binding affinity are capable of binding to TCR at predicted rank < 2%. The integrated model achieved higher accuracy for ranking immunogenic neopeptides than the conventional NetMHCpan tool solely relying on peptide-HLA-I binding features.
Conclusions
Our study presents an efficient process to select and prioritize neoantigens exhibiting both HLA presentation and immunogenicity for personalized cancer immunotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Medical Genetics Institute.
Funding
Nexcalibur Therapeutics.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
452P - The relationship between BCG immunotherapy and oxidative stress parameters in patients with non-muscle invasive bladder cancer
Presenter: Mukul Singh
Session: Poster Display
Resources:
Abstract
453P - Palonosetron plus megestrol acetate verses palonosetron plus dexamethasone in preventing moderately emetogenic chemotherapy-induced nausea and vomiting: A randomized, multicenter, crossover, phase II trial
Presenter: Qiaoqi Li
Session: Poster Display
Resources:
Abstract
454P - A multicenter randomized open-label phase II study investigating optimal antiemetic therapy for patients with advanced/recurrent gastric cancer treated with trastuzumab deruxtecan (T-DXd): EN-hance study
Presenter: Akira Ooki
Session: Poster Display
Resources:
Abstract
455P - Assessing model-predicted neurokinin-1 (NK1) receptor occupancy (RO) of netupitant to support efficacy over an extended time period
Presenter: Matti Aapro
Session: Poster Display
Resources:
Abstract
456P - Oxycodone/naloxone in moderate-to-severe cancer pain: A phase III study in China
Presenter: Ping Lu
Session: Poster Display
Resources:
Abstract
457P - Anticoagulation for terminal cancer patients with cancer associated venous thromboembolism
Presenter: Sang Bo Oh
Session: Poster Display
Resources:
Abstract
458P - Association between TSPAN15 and SLC44A2 genetic polymorphisms and venous thromboembolism in cancer patients
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
459P - Association between national health screening program and undertreatment of dyslipidemia in cancer survivors: A cross-sectional study
Presenter: Sujeong Shin
Session: Poster Display
Resources:
Abstract
460P - Group to grow: A systematic review of group-based interventions for post-traumatic growth on cancer patients
Presenter: Dyta William
Session: Poster Display
Resources:
Abstract
461P - A randomized controlled trial of yoga in locally advanced non-small cell lung cancer patients receiving chemoradiotherapy
Presenter: Indranil Khan
Session: Poster Display
Resources:
Abstract